Prescription Rizatriptan Benzoate Tablets Recalled for Chemical Impurity
Glenmark Pharmaceuticals recalls Rizatriptan Benzoate 5mg tablets due to excess N-Nitroso Desmethyl Rizatriptan impurity. The nationwide recall affects 3,480 cartons with lots 19233788 and 19224445.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a chemical impurity (N-Nitroso Desmethyl Rizatriptan) exceeding acceptable limits due to manufacturing control deviations. With no reported illnesses or injuries, this represents a risk-of-harm situation where preventive action is warranted, consistent with High severity classification.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling 3,480 cartons of Rizatriptan Benzoate Tablets USP, 5mg across the United States due to a manufacturing quality deviation. Testing identified N-Nitroso Desmethyl Rizatriptan impurity levels that exceed FDA acceptable limits.
The affected products include Lot 19233788 (expiration 9/2025) and Lot 19224445 (expiration 9/2024). These tablets are distributed nationwide with NDC codes 68462-465-99 and associated package codes.
Consumers taking Rizatriptan Benzoate from the affected lots should consult their healthcare provider or pharmacist immediately. Do not discontinue use of the medication without medical guidance, as doing so may affect migraine treatment. Return unused medication to the pharmacy.
Healthcare providers should identify patients who received affected lots and consider alternative treatments or re-dispensing from unaffected inventory.
The recalled product
- Product
- RIZATRIPTAN BENZOATE (RIZATRIPTAN BENZOATE)
- Brand
- RIZATRIPTAN BENZOATE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Affected units
- 3,480
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: 19233788
- Exp. 9/2025 Lot#: 19224445
- Exp. 9/2024
UPCs (2)
- 0368462465998
- 0368462466995
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · RIZATRIPTAN BENZOATE
- HighRizatriptan 5 mg tablets exceed the acceptable intake limit for nitrosamine
FDA (Drugs) · 2025-07-23
- HighRizatriptan 10 mg tablets exceed the acceptable intake limit for nitrosamine
FDA (Drugs) · 2025-07-23
- HighFDA Recalls Rizatriptan Benzoate Tablets for Manufacturing Impurity
FDA (Drugs) · 2024-06-12
- HighRizatriptan Benzoate Tablets Recalled for Excessive N-Nitroso Impurity
FDA (Drugs) · 2024-06-12
- HighPrescription migraine drug recalled for manufacturing impurity above FDA limit
FDA (Drugs) · 2024-06-12
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08